Eternal Rye – Improving Plant Breeding Methods

User story from Martin Luther University Halle.

Öppen frågestund: Regulatory Opportunities for Rare Diseases/Orphan Products in US and EU

Anmäl dig till vår nästa session av Office Hours den 28 februari klockan 15:00 (svensk tid), en öppen frågestund om utveckling av särläkemedel (orphan drugs).

Fuskanklagat pharmabolag lägger ner alzheimerprojekt

Amerikanska Cassava Sciences avbryter utvecklingen av sin läkemedelskandidat inom Alzheimers sjukdom efter misslyckande i en fas III-studie

HAB Nicolai Johannsen

Åsa Uppströmer ny vd för Pharma Relations

Pharma Relations har anställt Åsa Uppströmer som ny vd.

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

“You discover one thing – and then 10 new questions arise”

COVID-19, diabetes, heart disease, and the impact of dog ownership on humans are just some of multitasker Tove Fall’s areas of research. However, her current fo...

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

How Volume EM Advances Life Science Research

Free webinar series.

Webinar: Medtech quality and regulatory compliance

This webinar is for you who are developing or planning to develop a medical device, combination, or borderline product. In one hour, we will discuss what you ne...

Recipharm divests five Swedish plants

Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...

Storbolag i gräl om hiv-läkemedel

En träta om påstått vilseförande marknadsföring av hiv-läkemedel mellan läkemedelsbolagen Gilead och Glaxo Smith Kline (GSK) har nu avgjorts – till den senares fördel.

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

Digital Temperature Sensors from ZEISS

New Metrology Expert Tip video.

Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide

AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

Fyra pilotprojekt utvalda i life science-satsning

Bridge Sweden, projektet som går ut på underlätta identifiering och produktion av nya läkemedel, har valt ut sina första projekt.

Precision and accuracy in liquid handling

How to evaluate and optimize liquid handling performance

Jan Holmgren to receive award for the development of cholera vaccine

Researcher Jan Holmgren is being awarded for the development of the first effective drinkable cholera vaccine. The award is given by the International Vaccine I...

Karlstadprofessor prisas för insatser inom kromatografi

Torgny Fornstedt, professor i analytisk kemi vid Karlstads universitet, har tilldelats J.F.K. Huber Lecture Award för ”banbrytande bidrag inom fundamental först...

Hon får tungt uppdrag i Astra Zeneca – ersätter frihetsberövad Kinachef

Astra Zeneca utser Iskra Reic till Executive Vice President (EVP), International. Det betyder att hon får ansvar för bolagets övergripande strategi i stora dela...

Exploring Molecular Dynamics with Raster Image Correlation Spectroscopy

Case study by ZEISS Microscopy.

Introducing ZEISS arivis Pro 4.2

ZEISS arivis software enhances custom microscopy image analysis.

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...